A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate patient preference factors comparing two clindamycin/benzoyl peroxide gels. One dispensed in a pump presentation, the other in a tube presentation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clindamycin 1% / benzoyl peroxide 5% gel pump

Intervention Type DRUG

clindamycin 1% / benzoyl peroxide 5% tube

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with a clinical diagnosis of acne vulgaris of mild to moderate severity
2. Females of childbearing potential, in addition to having a negative urine pregnancy test at Visit 1, must be willing to use an acceptable form of birth control during the study.
3. Patients 18 years of age or older must provide Institutional Review Board (IRB) approved written informed consent. Patients under 18 years of age must have IRB approved written informed consent from a parent or legal guardian. Patients 12 - 17 years of age must complete an IRB approved assent form for minors.
4. Patients must be willing and able to understand the requirements of the study, abide by the restrictions, apply the medication as instructed, and return for the required study visits.
5. Patients must be in good health and free from any clinically significant disease, other than acne vulgaris, that might interfere with the study evaluations.
6. Patients who use make-up must have used the same brand of make-up for a minimum period of 2 weeks prior to Baseline and agree to not change make-up brands or types during the study.

Exclusion Criteria

1. Patients who are pregnant, nursing, or planning a pregnancy within the study period.
2. Patients who have more than 2 nodulo-cystic lesions on the face, excluding the nose.
3. Patients who have a known hypersensitivity to any ingredients in the test products including clindamycin and benzoyl peroxide.
4. Patients who have been treated with prescription and/or over-the-counter topical products, or had a procedure performed that may impact study assessments.
5. Patients who have any systemic or dermatological disorder that has the potential to interfere with the evaluations (e.g., rosacea, seborrheic dermatitis, perioral dermatitis, corticosteroid-induced acne vulgaris, carcinoid syndrome, mastocytosis, acneform eruptions caused by medication, facial psoriasis, facial eczema, etc.).
6. Patients with clinically significant unstable medical disorders, life-threatening disease, or current malignancies.
7. Patients who engage in activities that involve excessive or prolonged exposure to sunlight.
8. Patients who consume excessive amounts of alcohol, abuse drugs, or have any condition that would compromise compliance with this protocol.
9. Patients who have been treated with an investigational drug or investigational device within a period of 30 days prior to study entry.
10. Alcoholic toners, astringents, medicated topical preparations (prescriptions and over-the-counter), or medicated make-up on the facial treatment area.
11. Abrasive cleansers or washes to the facial area.
12. New cosmetics, or new cleansers applied to the face.
13. Patients must not wear make-up at the visits, so as not to interfere with the evaluations.
14. Patients should not use a sauna within 48 hours prior to each visit.

Minimum Eligible Age

12 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Phyllis Diener, MT, ASCP

Role: STUDY_DIRECTOR

Sanofi

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DL6021-0505

Identifier Type: -

Identifier Source: org_study_id